Medtronic plc announced positive results from the Enable Hernia Repair clinical study, evaluating the performance of the Hugo™ robotic-assisted surgery (RAS) system in inguinal and ventral hernia repair procedures. The study met both primary safety and effectiveness endpoints.
This marks the first-ever Investigational Device Exemption (IDE) clinical study completed for robotic-assisted hernia surgery in the United States. Key findings included a surgical success rate of 99.5% for inguinal and 98.9% for ventral hernia repairs, with low surgical site event rates.
The study builds on growing evidence for the Hugo system, which is already in clinical use in over 25 countries. Medtronic plans to submit for a U.S. urology indication later in its current fiscal year, followed by planned indication expansions into hernia repair and gynecology, positioning Hugo as a significant growth driver.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.